Future research should also focus on elucidating the upstream regulatory mechanisms governing GCNT2 expression, exploring its potential as a biomarker for disease staging or treatment response, and investigating the broader interplay between GCNT2-mediated glycosylation and other galectins beyond Gal-3 and Gal-8 to better understand their collective impact on melanoma progression and metastatic behavior. This evidence concerns the gene LGALS3 and melanoma.